
|Videos|July 24, 2014
Observation Versus Treatment in Men with Prostate Cancer
Author(s)Peter Yu, MD
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <
Advertisement
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels.
Clinical Pearls:
- One of the studies presented at the 2014 ASCO Annual Meeting reviewed data of men who decided to wait or pursue treatment.
- Results of this study showed there was no difference in survival regardless of their decision.
- Men and doctors can now better discuss remaining on observation or starting treatment.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































